New hope pill tested for tough blood cancers
NCT ID NCT06146257
Summary
This is the first study in people to test a new oral medication called GLB-001. It aims to find a safe and effective dose for adults with advanced forms of acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to other treatments. The main goals are to understand the drug's safety, how the body processes it, and to see if it shows any early signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alliance for Multispecialty Research, LLC
TERMINATEDMerriam, Kansas, 66204, United States
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center-David H. Koch Center
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Roswell Park Comprehensive Cancer Center
TERMINATEDBuffalo, New York, 14263, United States
-
University of California Irvine
TERMINATEDIrvine, California, 92697, United States
-
University of Kansas Medical Center Research Institute, Inc.
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas M. D. Anderson Cancer Center
TERMINATEDHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.